Susanne M. Lang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Susanne M. Lang has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Helmut Schiffl
Department of Internal Medicine IV, University Hospital Munich, Munich, Germany
7 shared publications Helmut Schiffl
Department of Internal Medicine IV, Nephrology, University Hospital Munich, Munich, Germany
4 shared publicationsAlex Rice
3 shared publicationsAnand Devaraj
3 shared publicationsAndreas Günther
3 shared publications- Andrew Gordon Nicholson
Department of Histopathology, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, and National Heart and Lung Institute, Imperial College London , London
3 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8648
Hospital Costs and Pleural Complications of Electromagnetic Navigational Bronchoscopy Versus CT-Guided Transthoracic Needle Biopsy: A German Multicentre Matched Analysis
Background/Objectives: Electromagnetic navigational bronchoscopy (ENB) and CT-guided transthoracic needle biopsy (TTNB) are established approaches to sampling peripheral pulmonary lesions. Comparative real-world data on procedure-associated pleural complications and hospital resource use remain limited. We compared coded pleural complications, length of stay, hospital costs and reimbursement after ENB versus TTNB in German inpatient care. Methods: This retrospective multicentre analysis used fully anonymised administrative hospital cost and reimbursement data from nine German hospitals between January 2023 and December 2024. Of 2904 inpatient cases (590 ENB and 2314 TTNB), 536 matched pairs were generated by 1:1 nearest-neighbour propensity-score matching without replacement using age and sex, with exact matching on adjacent diagnosis-related group (ADRG2). Outcomes were coded pneumothorax, coded pneumothorax requiring chest-tube drainage, length of stay, total hospital costs and reimbursement. Results: In the matched cohort, mean age was 68.2 ± 10.6 years after TTNB and 68.5 ± 10.4 years after ENB; the male-to-female ratio was 1.34 and 1.36, respectively. Coded pneumothorax occurred less frequently after ENB than after TTNB (4.1% vs. 13.1%); in matched-pair logistic regression, ENB was associated with lower odds of coded pneumothorax (OR 0.28, 95% CI 0.17–0.47; p < 0.001). Coded pneumothorax requiring chest-tube drainage occurred in 3.4% versus 12.9%, respectively. Median length of stay was shorter after ENB (2 [IQR 1–4] vs. 3 [1–8] days; p < 0.001), whereas median hospital costs were higher (€5793 [4670–7466] vs. €3739 [1995–7514]; p < 0.001). Median reimbursement was €3366 in both groups (p = 0.186). Conclusions: In this German inpatient cohort, ENB was associated with fewer coded pleural complications and shorter hospital stays than TTNB, but with higher hospital costs despite similar reimbursement. These findings characterise system-specific inpatient resource use and do not establish comparative clinical superiority or cost-effectiveness.
- 6 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8648
Open AccessHospital Costs and Pleural Complications of Electromagnetic Navigational Bronchoscopy Versus CT-Guided Transthoracic Needle Biopsy: A German Multicentre Matched Analysis
Background/Objectives: Electromagnetic navigational bronchoscopy (ENB) and CT-guided transthoracic needle biopsy (TTNB) are established approaches to sampling peripheral pulmonary lesions. Comparative real-world data on procedure-associated pleural complications and hospital resource use remain limited. We compared coded pleural complications, length of stay, hospital costs and reimbursement after ENB versus TTNB in German inpatient care. Methods: This retrospective multicentre analysis used fully anonymised administrative hospital cost and reimbursement data from nine German hospitals between January 2023 and December 2024. Of 2904 inpatient cases (590 ENB and 2314 TTNB), 536 matched pairs were generated by 1:1 nearest-neighbour propensity-score matching without replacement using age and sex, with exact matching on adjacent diagnosis-related group (ADRG2). Outcomes were coded pneumothorax, coded pneumothorax requiring chest-tube drainage, length of stay, total hospital costs and reimbursement. Results: In the matched cohort, mean age was 68.2 ± 10.6 years after TTNB and 68.5 ± 10.4 years after ENB; the male-to-female ratio was 1.34 and 1.36, respectively. Coded pneumothorax occurred less frequently after ENB than after TTNB (4.1% vs. 13.1%); in matched-pair logistic regression, ENB was associated with lower odds of coded pneumothorax (OR 0.28, 95% CI 0.17–0.47; p < 0.001). Coded pneumothorax requiring chest-tube drainage occurred in 3.4% versus 12.9%, respectively. Median length of stay was shorter after ENB (2 [IQR 1–4] vs. 3 [1–8] days; p < 0.001), whereas median hospital costs were higher (€5793 [4670–7466] vs. €3739 [1995–7514]; p < 0.001). Median reimbursement was €3366 in both groups (p = 0.186). Conclusions: In this German inpatient cohort, ENB was associated with fewer coded pleural complications and shorter hospital stays than TTNB, but with higher hospital costs despite similar reimbursement. These findings characterise system-specific inpatient resource use and do not establish comparative clinical superiority or cost-effectiveness.
- Open Access
- 15 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Hippo pathway activation drives fibrogenic remodelling in influenza A virus-infected lung fibroblasts
Background: Pulmonary fibrosis is a progressive and often fatal interstitial lung disease with largely undefined aetiology. Alveolar macrophages and lung fibroblasts play key roles in maladaptive tissue remodelling; however, the cellular and molecular mechanisms underlying their coordinated fibrotic responses remain incompletely characterised. Methods: Following influenza A virus (IAV) infection, viral load, cytokine release and transcriptomic changes were analysed. To assess indirect effects on fibrosis, IMR-90 fibroblasts were treated with conditioned media from infected alveolar macrophage-like (AML) cells. Direct IAV infection of IMR-90 cells was also performed to evaluate changes in the Hippo signalling pathway and fibrotic marker expression using microarray and transcriptomic approaches. Results: For the first time, AML cells were successfully infected with IAV, validating this model for studying pathogen-driven exacerbation of fibrosis in ageing lungs. Transcriptomic and protein-level analyses revealed that IAV promotes fibrogenesis in fibroblasts through two distinct mechanisms: 1) indirectly, via pro-inflammatory and pro-fibrotic mediators released by infected macrophages; and 2) directly, through viral-induced modulation of the Hippo signalling pathway, resulting in upregulation of key fibrotic markers such as CTGF, fibronectin and collagen I. Conclusions: These findings provide novel mechanistic insights into macrophage–fibroblast crosstalk in the context of viral infection and fibrosis. They suggest that dysregulation of these interactions contributes to the susceptibility of the ageing lung to fibrotic remodelling following respiratory viral infections and may inform future therapeutic interventions targeting Hippo pathway signalling.
- 15 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open AccessHippo pathway activation drives fibrogenic remodelling in influenza A virus-infected lung fibroblasts
Background: Pulmonary fibrosis is a progressive and often fatal interstitial lung disease with largely undefined aetiology. Alveolar macrophages and lung fibroblasts play key roles in maladaptive tissue remodelling; however, the cellular and molecular mechanisms underlying their coordinated fibrotic responses remain incompletely characterised. Methods: Following influenza A virus (IAV) infection, viral load, cytokine release and transcriptomic changes were analysed. To assess indirect effects on fibrosis, IMR-90 fibroblasts were treated with conditioned media from infected alveolar macrophage-like (AML) cells. Direct IAV infection of IMR-90 cells was also performed to evaluate changes in the Hippo signalling pathway and fibrotic marker expression using microarray and transcriptomic approaches. Results: For the first time, AML cells were successfully infected with IAV, validating this model for studying pathogen-driven exacerbation of fibrosis in ageing lungs. Transcriptomic and protein-level analyses revealed that IAV promotes fibrogenesis in fibroblasts through two distinct mechanisms: 1) indirectly, via pro-inflammatory and pro-fibrotic mediators released by infected macrophages; and 2) directly, through viral-induced modulation of the Hippo signalling pathway, resulting in upregulation of key fibrotic markers such as CTGF, fibronectin and collagen I. Conclusions: These findings provide novel mechanistic insights into macrophage–fibroblast crosstalk in the context of viral infection and fibrosis. They suggest that dysregulation of these interactions contributes to the susceptibility of the ageing lung to fibrotic remodelling following respiratory viral infections and may inform future therapeutic interventions targeting Hippo pathway signalling.
- Open Access
Beyond Tumor Suppression: The Multifaceted Functions of HOPX in Tissue Differentiation, Metabolism, and Immunity
The transcription factor homeodomain-only protein X (HOPX) is the smallest member of the homeodomain protein family. Lacking a DNA-binding domain, it acts as a co-effector, interacting with other transcription factors such as serum response factor (SRF) and GATA-binding factor 6 (GATA6) to regulate the differentiation and development of the heart and lung. HOPX exerts a tumor-suppressive function in various types of epithelial-derived carcinoma, while it promotes oncogenic effects in mesenchymal-derived sarcoma, indicating a distinct role of HOPX in the two major types of the malignancy. In addition, accumulating evidence shows that HOPX is expressed in the immune system and involved in the differentiation of immune cells. Recently, the emerging role of HOPX in metabolism has gained attention. This review describes the identification of HOPX in various tissues and discusses its role in carcinogenesis, as well as its functions in tissue differentiation, lipid metabolism, immunity, and the tumor microenvironment. The participation of HOPX in carcinogenesis and immunity implies that it may serve as a potential enhancer in tumor immunotherapy.
Open AccessBeyond Tumor Suppression: The Multifaceted Functions of HOPX in Tissue Differentiation, Metabolism, and Immunity
The transcription factor homeodomain-only protein X (HOPX) is the smallest member of the homeodomain protein family. Lacking a DNA-binding domain, it acts as a co-effector, interacting with other transcription factors such as serum response factor (SRF) and GATA-binding factor 6 (GATA6) to regulate the differentiation and development of the heart and lung. HOPX exerts a tumor-suppressive function in various types of epithelial-derived carcinoma, while it promotes oncogenic effects in mesenchymal-derived sarcoma, indicating a distinct role of HOPX in the two major types of the malignancy. In addition, accumulating evidence shows that HOPX is expressed in the immune system and involved in the differentiation of immune cells. Recently, the emerging role of HOPX in metabolism has gained attention. This review describes the identification of HOPX in various tissues and discusses its role in carcinogenesis, as well as its functions in tissue differentiation, lipid metabolism, immunity, and the tumor microenvironment. The participation of HOPX in carcinogenesis and immunity implies that it may serve as a potential enhancer in tumor immunotherapy.
- 20 June 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (12) , 4169-4176
Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions
Purpose COVID-19 infection is associated with a high burden of acute or acute on chronic kidney injury (AKI), particularly in critically ill patients. Given the large numbers of COVID-19 survivors, characterization of long-term adverse kidney effects of COVID-19 have important implications for post-COVID-19 care. Methods This narrative review provides a summary of epidemiologic evidence for post-COVID kidney disorders. Results Precise post-COVID renal data are scarce. The true burden of long-COVID chronic kidney disease (CKD) remains unknown owing to under-recognition, under-diagnosis, clinical heterogeneity of patients, incomplete follow-up, and temporal trends in critical COVID-19 disease across waves of the pandemic. Collectively, the few well-designed studies assessing the impact of long-COVID on kidney health found that the overwhelming majority of patients with normal renal function at admission and without AKI during acute COVID-19 disease preserved kidney function. Post-infection kidney function trajectories of patients who experience a loss of renal function vary. Kidney function may decline gradually even in non-hospitalized patients, hospitalized patients may experience a rapid loss of kidney function 6–12 months after COVID-19 diagnosis or hospital discharge resulting from AKI during the acute phase of the disease. End-stage renal disease may occur after non-recovery from AKI and rapid progression of pre-existing CKD. Multiple mechanisms may trigger post-COVID CKD including maladaptive repair after AKI, or progression of renal lesions of systemic co-morbidities, persistence of the virus and dysregulation of inflammatory cytokines. Conclusions The COVID-19 pandemic has significantly impacted and may continue to have an impact on kidney health. Patients at risk have a higher propensity to develop critical COVID-19 disease. Post-COVID-19 care must pay close attention to renal function in patients discharged from hospital.
- 20 June 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (12) , 4169-4176
Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions
Purpose COVID-19 infection is associated with a high burden of acute or acute on chronic kidney injury (AKI), particularly in critically ill patients. Given the large numbers of COVID-19 survivors, characterization of long-term adverse kidney effects of COVID-19 have important implications for post-COVID-19 care. Methods This narrative review provides a summary of epidemiologic evidence for post-COVID kidney disorders. Results Precise post-COVID renal data are scarce. The true burden of long-COVID chronic kidney disease (CKD) remains unknown owing to under-recognition, under-diagnosis, clinical heterogeneity of patients, incomplete follow-up, and temporal trends in critical COVID-19 disease across waves of the pandemic. Collectively, the few well-designed studies assessing the impact of long-COVID on kidney health found that the overwhelming majority of patients with normal renal function at admission and without AKI during acute COVID-19 disease preserved kidney function. Post-infection kidney function trajectories of patients who experience a loss of renal function vary. Kidney function may decline gradually even in non-hospitalized patients, hospitalized patients may experience a rapid loss of kidney function 6–12 months after COVID-19 diagnosis or hospital discharge resulting from AKI during the acute phase of the disease. End-stage renal disease may occur after non-recovery from AKI and rapid progression of pre-existing CKD. Multiple mechanisms may trigger post-COVID CKD including maladaptive repair after AKI, or progression of renal lesions of systemic co-morbidities, persistence of the virus and dysregulation of inflammatory cytokines. Conclusions The COVID-19 pandemic has significantly impacted and may continue to have an impact on kidney health. Patients at risk have a higher propensity to develop critical COVID-19 disease. Post-COVID-19 care must pay close attention to renal function in patients discharged from hospital.
- 12 November 2024
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (4) , 1199-1205
E -cigarettes and kidney health: current knowledge and future perspectives
Background Chronic conventional cigarette smoking has been closely linked to incident chronic kidney disease (CKD) in the general population. It is associated with the acceleration of pre-existing CKD and failure of kidney allograft function. Cessation of conventional cigarette smoking is effective in reducing the increased risk of smoking induced kidney damage. Methods This narrative review summarizes current knowledge and future study perspectives of the impact of e-cigarettes (e-cigs) use on kidney health. Results The past decade has seen a dramatic increase in the use of electronic nicotine delivering systems, also called e-cigs. Compared to conventional cigarette smoking, little is known concerning the effects of e-cigs use on kidney health. A few cross-sectional studies suggest an association between vaping and kidney damage (albuminuria, reduction in estimated glomerular filtration rate) in adolescents and young adults. Furthermore, limited animal experiments indicate that e-cigs constituents/aerosols may lead to structural and functional kidney damage. The renal health effects of e-cigs remain largely uncertain and make it difficult to draw definitive conclusions about e-cigs use and kidney health. The relatively new popularity of e-cigs, the wide variability in device design and e-liquid formulations, and the lack of standardized methods to measure daily or life-long e-cigs exposure make it challenging to conduct comprehensive long-term studies. Conclusions Nephrologists should actively address smoking habits in their patients and urge cessation of conventional cigarette smoking as well as e-cigs use to prevent CKD progression and improve overall health.
- 12 November 2024
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (4) , 1199-1205
E -cigarettes and kidney health: current knowledge and future perspectives
Background Chronic conventional cigarette smoking has been closely linked to incident chronic kidney disease (CKD) in the general population. It is associated with the acceleration of pre-existing CKD and failure of kidney allograft function. Cessation of conventional cigarette smoking is effective in reducing the increased risk of smoking induced kidney damage. Methods This narrative review summarizes current knowledge and future study perspectives of the impact of e-cigarettes (e-cigs) use on kidney health. Results The past decade has seen a dramatic increase in the use of electronic nicotine delivering systems, also called e-cigs. Compared to conventional cigarette smoking, little is known concerning the effects of e-cigs use on kidney health. A few cross-sectional studies suggest an association between vaping and kidney damage (albuminuria, reduction in estimated glomerular filtration rate) in adolescents and young adults. Furthermore, limited animal experiments indicate that e-cigs constituents/aerosols may lead to structural and functional kidney damage. The renal health effects of e-cigs remain largely uncertain and make it difficult to draw definitive conclusions about e-cigs use and kidney health. The relatively new popularity of e-cigs, the wide variability in device design and e-liquid formulations, and the lack of standardized methods to measure daily or life-long e-cigs exposure make it challenging to conduct comprehensive long-term studies. Conclusions Nephrologists should actively address smoking habits in their patients and urge cessation of conventional cigarette smoking as well as e-cigs use to prevent CKD progression and improve overall health.
- Open Access
- 16 August 2024
- Published by Herald Scholarly Open Access in Journal of Clinical Studies & Medical Case Reports
- Vol. 11 (4) , 1-5
High Flow Oxygen Therapy and Secondary Spontaneous Pneumothorax: A Case Report
Treatment of secondary spontaneous pneumothorax in high-risk surgical patients with chronic pulmonary disease is a challenge in standard and emergency care. The observation that supplementary oxygen may lead to better reabsorption of pneumothorax has been known for over 50 years. It can help to avoid potential high-risk interventions or surgery in multimorbid patients.
- 16 August 2024
- Published by Herald Scholarly Open Access in Journal of Clinical Studies & Medical Case Reports
- Vol. 11 (4) , 1-5
Open AccessHigh Flow Oxygen Therapy and Secondary Spontaneous Pneumothorax: A Case Report
Treatment of secondary spontaneous pneumothorax in high-risk surgical patients with chronic pulmonary disease is a challenge in standard and emergency care. The observation that supplementary oxygen may lead to better reabsorption of pneumothorax has been known for over 50 years. It can help to avoid potential high-risk interventions or surgery in multimorbid patients.
- Open Access
- 27 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3773
Venous and Arterial Thromboembolism in Lung Cancer Patients: A Retrospective Analysis
Background: Patients with lung cancer face an increased incidence of venous (VTE) and arterial (ATE) thromboembolism. Risk factors for thrombosis remain unclear, particularly the impact of the use of immune checkpoint inhibitors (ICIs). We sought to compare the incidence of VTE and ATE in lung cancer patients receiving platinum-based therapy versus those receiving ICIs alone or in combination with chemotherapy and to validate the Khorana risk score for predicting VTE in the era of ICIs. Methods: A retrospective single-institution data analysis of 173 patients diagnosed with locally advanced or metastatic lung cancer at the Jena University hospital between 2015 and 2021. Results: The study revealed a high incidence of VTE (17.9%) and ATE (5.8%). The VTE risk was higher in patients diagnosed with adenocarcinoma (OR 0.29, 95% CI 0.09–0.93) than in patients with other histological types. A prior venous event was associated with an increased risk of recurrent VTE (OR 4.46, 95% CI 1.20–16.63). The incidence of thrombosis under first-line platinum-based chemotherapy did not differ from the incidence under ICIs (p = 0.19). There were no differences in the subgroup of patients who received ICIs alone or combined immunochemotherapy (p = 0.43). The Khorana score failed to predict the risk of VTE correctly. Conclusions: We did not find evidence supporting the theory that ICI therapy (alone or combined) increases the risk of thrombotic events. Adenocarcinoma and a prior history of VTE were strongly associated with an increased risk of VTE. Other scores for thrombotic risk assessment in lung cancer patients should be tested in prospective studies.
- 27 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3773
Open AccessVenous and Arterial Thromboembolism in Lung Cancer Patients: A Retrospective Analysis
Background: Patients with lung cancer face an increased incidence of venous (VTE) and arterial (ATE) thromboembolism. Risk factors for thrombosis remain unclear, particularly the impact of the use of immune checkpoint inhibitors (ICIs). We sought to compare the incidence of VTE and ATE in lung cancer patients receiving platinum-based therapy versus those receiving ICIs alone or in combination with chemotherapy and to validate the Khorana risk score for predicting VTE in the era of ICIs. Methods: A retrospective single-institution data analysis of 173 patients diagnosed with locally advanced or metastatic lung cancer at the Jena University hospital between 2015 and 2021. Results: The study revealed a high incidence of VTE (17.9%) and ATE (5.8%). The VTE risk was higher in patients diagnosed with adenocarcinoma (OR 0.29, 95% CI 0.09–0.93) than in patients with other histological types. A prior venous event was associated with an increased risk of recurrent VTE (OR 4.46, 95% CI 1.20–16.63). The incidence of thrombosis under first-line platinum-based chemotherapy did not differ from the incidence under ICIs (p = 0.19). There were no differences in the subgroup of patients who received ICIs alone or combined immunochemotherapy (p = 0.43). The Khorana score failed to predict the risk of VTE correctly. Conclusions: We did not find evidence supporting the theory that ICI therapy (alone or combined) increases the risk of thrombotic events. Adenocarcinoma and a prior history of VTE were strongly associated with an increased risk of VTE. Other scores for thrombotic risk assessment in lung cancer patients should be tested in prospective studies.
- Open Access
- 18 March 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-7
Smoking status, cadmium, and chronic kidney disease
Background: Chronic kidney disease (CKD) affects 10% of the general population in Western countries. Currently, CKD cannot be cured and there are only few strategies to prevent the onset of CKD, to reverse early stages of CKD, and to prevent the progression of established CKD to end-stage kidney disease. Cigarette smoking is a preventable cause of CKD.Methods: This narrative review analyses the cause–effect relationship between cigarette smoking and CKD and discusses the association of inhaled cadmium and smoking-induced kidney damage.Results: Cigarette smoking places individuals at risk for incident CKD. It accelerates the progression (decline in glomerular filtration rate, aggravation of proteinuria) of CKD to end-stage kidney disease (ESKD), and is associated with shortened kidney transplant graft survival. These harmful effects on kidney function/structure are dependent on the dose and duration of cigarette smoking. Smoking abstinence decreases the higher risk for proteinuria and CKD progression. Inhaled cadmium may be the biologic link between cigarette smoking and kidney dysfunction. Recent studies indicate that accumulation of cadmium in the blood mediates progression of CKD and places smokers at higher risk for all-cause mortality.Conclusions: Smoking cessation is an effective intervention to reduce the risk of onset and progression of CKD as well as to reduce smoking-attributable morbidity and mortality.
- 18 March 2024
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 10 (1) , 1-7
Open AccessSmoking status, cadmium, and chronic kidney disease
Background: Chronic kidney disease (CKD) affects 10% of the general population in Western countries. Currently, CKD cannot be cured and there are only few strategies to prevent the onset of CKD, to reverse early stages of CKD, and to prevent the progression of established CKD to end-stage kidney disease. Cigarette smoking is a preventable cause of CKD.Methods: This narrative review analyses the cause–effect relationship between cigarette smoking and CKD and discusses the association of inhaled cadmium and smoking-induced kidney damage.Results: Cigarette smoking places individuals at risk for incident CKD. It accelerates the progression (decline in glomerular filtration rate, aggravation of proteinuria) of CKD to end-stage kidney disease (ESKD), and is associated with shortened kidney transplant graft survival. These harmful effects on kidney function/structure are dependent on the dose and duration of cigarette smoking. Smoking abstinence decreases the higher risk for proteinuria and CKD progression. Inhaled cadmium may be the biologic link between cigarette smoking and kidney dysfunction. Recent studies indicate that accumulation of cadmium in the blood mediates progression of CKD and places smokers at higher risk for all-cause mortality.Conclusions: Smoking cessation is an effective intervention to reduce the risk of onset and progression of CKD as well as to reduce smoking-attributable morbidity and mortality.
- Open Access
The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer
Abnormal expression of ACSL members 1, 3, 4, 5, and 6 is frequently seen in human cancer; however, their clinical relevance is unclear. In this study, we analyzed the expression of ACSLs and investigated the effects of the ACSL inhibitor Triacsin C (TC) in lung cancer. We found that, compared to normal human bronchial epithelial (NHBE) cells, ACSL1, ACSL4, and ACSL6 were highly expressed, while ACSL3 and ACSL5 were lost in the majority of lung cancer cell lines. ACSL activity was associated with the expression levels of the ACSLs. In primary lung tumors, a higher expression of ACSL1, ACSL4, and ACSL5 was significantly correlated with adenocarcinoma (ADC). Moreover, ACSL5 was significantly reversely related to the proliferation marker Ki67 in low-grade tumors, while ACSL3 was positively associated with Ki67 in high-grade tumors. Combination therapy with TC and Gemcitabine enhanced the growth-inhibitory effect in EGFR wild-type cells, while TC combined with EGFR-TKIs sensitized the EGFR-mutant cells to EGFR-TKI treatment. Taken together, the data suggest that ACSL1 may be a biomarker for lung ADC, and ACSL1, ACSL4, and ACSL5 may be involved in lung cancer differentiation, and TC, in combination with chemotherapy or EGFR-TKIs, may help patients overcome drug resistance.
Open AccessThe Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer
Abnormal expression of ACSL members 1, 3, 4, 5, and 6 is frequently seen in human cancer; however, their clinical relevance is unclear. In this study, we analyzed the expression of ACSLs and investigated the effects of the ACSL inhibitor Triacsin C (TC) in lung cancer. We found that, compared to normal human bronchial epithelial (NHBE) cells, ACSL1, ACSL4, and ACSL6 were highly expressed, while ACSL3 and ACSL5 were lost in the majority of lung cancer cell lines. ACSL activity was associated with the expression levels of the ACSLs. In primary lung tumors, a higher expression of ACSL1, ACSL4, and ACSL5 was significantly correlated with adenocarcinoma (ADC). Moreover, ACSL5 was significantly reversely related to the proliferation marker Ki67 in low-grade tumors, while ACSL3 was positively associated with Ki67 in high-grade tumors. Combination therapy with TC and Gemcitabine enhanced the growth-inhibitory effect in EGFR wild-type cells, while TC combined with EGFR-TKIs sensitized the EGFR-mutant cells to EGFR-TKI treatment. Taken together, the data suggest that ACSL1 may be a biomarker for lung ADC, and ACSL1, ACSL4, and ACSL5 may be involved in lung cancer differentiation, and TC, in combination with chemotherapy or EGFR-TKIs, may help patients overcome drug resistance.
- Open Access
- 14 December 2023
- Published by S. Karger AG in Kompass Pneumologie
- Vol. 12 (1) , 18-21
Adenokarzinome der Lunge: Radiomics könnten prognostische Aussagen verbessern
Objective: To develop and validate a prediction model for early recurrence of stage I lung adenocarcinoma (LUAD) that combines radiomics features based on preoperative CT with tumour spread through air spaces (STAS). Materials and methods: The most recent preoperative thin-section chest CT scans and postoperative pathological haematoxylin and eosin-stained sections were retrospectively collected from patients with a postoperative pathological diagnosis of stage I LUAD. Regions of interest were manually segmented, and radiomics features were extracted from the tumour and peritumoral regions extended by 3 voxel units, 6 voxel units, and 12 voxel units, and 2D and 3D deep learning image features were extracted by convolutional neural networks. Then, the RAdiomics Integrated with STAS model (RAISm) was constructed. The performance of RAISm was then evaluated in a development cohort and validation cohort. Results: A total of 226 patients from two medical centres from January 2015 to December 2018 were retrospectively included as the development cohort for the model and were randomly split into a training set (72.6%, n = 164) and a test set (27.4%, n = 62). From June 2019 to December 2019, 51 patients were included in the validation cohort. RAISm had excellent discrimination in predicting the early recurrence of stage I LUAD in the training cohort (AUC = 0.847, 95% CI 0.762–0.932) and validation cohort (AUC = 0.817, 95% CI 0.625–1.000). RAISm outperformed single modality signatures and other combinations of signatures in terms of discrimination and clinical net benefits. Conclusion: We pioneered combining preoperative CT-based radiomics with STAS to predict stage I LUAD recurrence postoperatively and confirmed the superior effect of the model in validation cohorts, showing its potential to assist in postoperative treatment strategies.
- 14 December 2023
- Published by S. Karger AG in Kompass Pneumologie
- Vol. 12 (1) , 18-21
Open AccessAdenokarzinome der Lunge: Radiomics könnten prognostische Aussagen verbessern
Objective: To develop and validate a prediction model for early recurrence of stage I lung adenocarcinoma (LUAD) that combines radiomics features based on preoperative CT with tumour spread through air spaces (STAS). Materials and methods: The most recent preoperative thin-section chest CT scans and postoperative pathological haematoxylin and eosin-stained sections were retrospectively collected from patients with a postoperative pathological diagnosis of stage I LUAD. Regions of interest were manually segmented, and radiomics features were extracted from the tumour and peritumoral regions extended by 3 voxel units, 6 voxel units, and 12 voxel units, and 2D and 3D deep learning image features were extracted by convolutional neural networks. Then, the RAdiomics Integrated with STAS model (RAISm) was constructed. The performance of RAISm was then evaluated in a development cohort and validation cohort. Results: A total of 226 patients from two medical centres from January 2015 to December 2018 were retrospectively included as the development cohort for the model and were randomly split into a training set (72.6%, n = 164) and a test set (27.4%, n = 62). From June 2019 to December 2019, 51 patients were included in the validation cohort. RAISm had excellent discrimination in predicting the early recurrence of stage I LUAD in the training cohort (AUC = 0.847, 95% CI 0.762–0.932) and validation cohort (AUC = 0.817, 95% CI 0.625–1.000). RAISm outperformed single modality signatures and other combinations of signatures in terms of discrimination and clinical net benefits. Conclusion: We pioneered combining preoperative CT-based radiomics with STAS to predict stage I LUAD recurrence postoperatively and confirmed the superior effect of the model in validation cohorts, showing its potential to assist in postoperative treatment strategies.